SG11202009667UA - Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment - Google Patents

Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment

Info

Publication number
SG11202009667UA
SG11202009667UA SG11202009667UA SG11202009667UA SG11202009667UA SG 11202009667U A SG11202009667U A SG 11202009667UA SG 11202009667U A SG11202009667U A SG 11202009667UA SG 11202009667U A SG11202009667U A SG 11202009667UA SG 11202009667U A SG11202009667U A SG 11202009667UA
Authority
SG
Singapore
Prior art keywords
inhibitor
lag
combination
cancer treatment
hdac
Prior art date
Application number
SG11202009667UA
Other languages
English (en)
Inventor
René Bartz
Frank Hermann
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Ag filed Critical 4Sc Ag
Publication of SG11202009667UA publication Critical patent/SG11202009667UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202009667UA 2018-04-17 2019-04-17 Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment SG11202009667UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18167719 2018-04-17
PCT/EP2019/059940 WO2019202001A1 (en) 2018-04-17 2019-04-17 Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment

Publications (1)

Publication Number Publication Date
SG11202009667UA true SG11202009667UA (en) 2020-11-27

Family

ID=62017215

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009667UA SG11202009667UA (en) 2018-04-17 2019-04-17 Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment

Country Status (12)

Country Link
US (1) US20230201161A1 (zh)
EP (1) EP3781159A1 (zh)
JP (1) JP2021521234A (zh)
KR (1) KR20200143452A (zh)
CN (1) CN112055589A (zh)
AU (1) AU2019254578A1 (zh)
CA (1) CA3097087A1 (zh)
IL (1) IL277979A (zh)
MX (1) MX2020011002A (zh)
SG (1) SG11202009667UA (zh)
TW (1) TW202002968A (zh)
WO (1) WO2019202001A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021152495A1 (en) * 2020-01-28 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
GB202108718D0 (en) * 2021-06-18 2021-08-04 Immutep Sas Triple combination therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842820B2 (en) 2004-03-11 2010-11-30 4Sc Ag Sulfonylpyrroles
SI1861365T1 (sl) 2005-03-15 2009-12-31 4Sc Ag N-sulfonilpiroli in njihova uporaba kot inhibitorji histon deacetilaze
EP2100882A1 (en) * 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts

Also Published As

Publication number Publication date
EP3781159A1 (en) 2021-02-24
CN112055589A (zh) 2020-12-08
TW202002968A (zh) 2020-01-16
MX2020011002A (es) 2021-01-29
AU2019254578A1 (en) 2020-10-22
US20230201161A1 (en) 2023-06-29
WO2019202001A1 (en) 2019-10-24
IL277979A (en) 2020-11-30
CA3097087A1 (en) 2019-10-24
KR20200143452A (ko) 2020-12-23
JP2021521234A (ja) 2021-08-26

Similar Documents

Publication Publication Date Title
IL279991A (en) PD-1/PD-L1 inhibitors
IL276246A (en) PD-1/PD-L1 inhibitors
IL269466A (en) PD-1/PD-L1 inhibitors
MX2022001834A (es) Terapias combinadas de inhibidores de hdac e inhibidores de pd-1.
EP3664829A4 (en) LIAISON OFFICERS AT PD-1 AND PD-L1
MX2022001447A (es) Terapias combinadas de inhibidores de hdac e inhibidores de pd-l1.
IL254131A0 (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
EP3669872A4 (en) FORMYL PYRIDINE DERIVATIVE WITH PD-L1 INHIBITORING EFFECT, MANUFACTURING METHOD FOR IT AND USE THEREOF
IL284837A (en) A pharmaceutical combination containing tno155 and a pd-1 inhibitor
SG11202010423VA (en) COMBINED INHIBITION OF PD-1/PD-L1, TGFß AND DNA-PK FOR THE TREATMENT OF CANCER
IL263110A (en) Combined treatment of notch and pd-1 or pd-l1 inhibitors
IL287765A (en) TIGIT and FDI-1/TIGIT binding molecules
IL289037A (en) Indanes as inhibitors of pd-l1
IL277979A (en) Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment
IL282654A (en) Method and medicament for treating cancer that does not respond to a PD-1/PD-L1 signaling inhibitor
IL288564A (en) Pressure-adjusted watering and spraying
EP3632430A4 (en) AGENT FOR THE PREVENTION OR TREATMENT OF SPINOCEREBELLOUS ATAXIA
IL282273A (en) History of Urea for the treatment and prevention of cancer
IL270948A (en) Combination of regorfenib and PD-1/PD-L1(2) for cancer treatment
EP3769759A4 (en) AGENTS FOR TREATMENT OF EPILEPSY
EP3609578A4 (en) PHARMACEUTICAL COMBINATION AND ITS USE FOR THE TREATMENT OF SYNUCLEINOPATHIES
IL281670A (en) Combination of PD-1 antagonist, ATR inhibitor and platinating agent for cancer treatment
EP3675841A4 (en) NEW CHINOCHALCONE COMPOUND AND ITS USES FOR TREATING CANCER OR INFLAMMATION
EP4056188A4 (en) MEANS FOR PREVENTING OR TREATING ARRHYTHMIA AND DEVICE FOR PREVENTING OR TREATING ARRHYTHMIA
AU2017904072A0 (en) Methods and compositions for treating or preventing seizures